跳转至内容
Merck
CN
  • Evaluation of different perfusion durations in direct hemoperfusion with polymyxin B-immobilized fiber column therapy for acute exacerbation of interstitial pneumonias.

Evaluation of different perfusion durations in direct hemoperfusion with polymyxin B-immobilized fiber column therapy for acute exacerbation of interstitial pneumonias.

Blood purification (2011-03-05)
Masato Kono, Takafumi Suda, Noriyuki Enomoto, Yutaro Nakamura, Yusuke Kaida, Dai Hashimoto, Naoki Inui, Tomoaki Mizuguchi, Akihiko Kato, Toshihiro Shirai, Hirotoshi Nakamura, Kingo Chida
摘要

Recently, the potential therapeutic effect of direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) has been reported for acute exacerbation of interstitial pneumonia (AE-IP), a highly morbid clinical event; however, there is no consensus on the appropriate procedure for PMX-DHP. We examined the appropriate perfusion duration of PMX-DHP for AE-IP. AE-IP patients receiving PMX-DHP were divided into two groups: short-duration group (≤6 h) (n = 5) and long-duration group (12 h) (n = 12). ThePaO(2)/FiO(2) (P/F) ratio increased immediately after PMX-DHP in the two groups. In the long-duration group, the P/F ratio continued to increase over the following 7 days, while, in the short-duration group, the P/F ratio declined again 3 days after therapy. The survival rate 30 days after PMX-DHP was significantly higher in the long-duration group than in the short-duration group. A long perfusion duration of PMX-DHP is more efficacious for AE-IP than a short perfusion duration.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
二乙基-1,4-二氢-2,4,6-三甲基-3,5-吡啶二羧酸酯, 99%